Protease-Activated Receptors in Cardiovascular Diseases

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Circulation

• Publication date

  2006-09-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.105.574830PMID 16952995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis

  2006cited by this paper
• Pharmacology and In Vivo Efficacy of Pepducins in Hemostasis and Arterial Thrombosis

  2006cited by this paper
• Handbook of cell-penetrating peptides

  2006cited by this paper
• 14 Pharmacology and In Vivo Efficacy of Pepducins in Hemostasis and Arterial Thrombosis

  2006cited by this paper
• Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.

  2005cited by this paper
• Reversing systemic inflammatory response syndrome with chemokine receptor pepducins

  2005cited by this paper
• Protease‐activated receptors‐1 and ‐2 can mediate endothelial barrier protection: role in factor Xa signaling

  2005cited by this paper
• Neutrophils and the kallikrein–kinin system in proteinase‐activated receptor 4‐mediated inflammation in rodents

  2005cited by this paper
• Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation.

  2005cited by this paper
• Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.

  2005cited by this paper
• PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.

  2005cited by this paper
• Synergistic Effect of Thrombin on Collagen-Induced Platelet Procoagulant Activity Is Mediated Through Protease-Activated Receptor-1

  2005cited by this paper
• Differences in Matrix Metalloproteinase-1 and Matrix Metalloproteinase-12 Transcript Levels Among Carotid Atherosclerotic Plaques With Different Histopathological Characteristics

  2004cited by this paper
• Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.

  2004cited by this paper
• Protease-activated receptors: contribution to physiology and disease.

  2004cited by this paper
• Thrombin and Phenotypic Modulation of the Endothelium

  2004cited by this paper
• Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha(9)beta(1).

  2004cited by this paper
• Tissue factor-factor VIIa signaling.

  2004cited by this paper
• Proteinase‐activated receptor‐4: evaluation of tethered ligand‐derived peptides as probes for receptor function and as inflammatory agonists in vivo

  2004cited by this paper
• Plasmin-induced Migration Requires Signaling through Protease-activated Receptor 1 and Integrin α9β1*

  2004cited by this paper
• Inhibition of platelet thromboxane receptor function by a thrombin receptor–targeted pepducin

  2003cited by this paper
• Scientific and therapeutic advances in antiplatelet therapy

  2003cited by this paper
• Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding.

  2003cited by this paper
• Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates

  2003cited by this paper
• Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells.

  2003cited by this paper
• Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage.

  2003cited by this paper
• Distinct signals via Rho GTPases and Src drive shape changes by thrombin and sphingosine-1-phosphate in endothelial cells.

  2002cited by this paper
• Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides

  2002cited by this paper
• Role of the PAR4 Thrombin Receptor in Stabilizing Platelet-platelet Aggregates as Revealed by a Patient with Hermansky-Pudlak Syndrome

  2002cited by this paper
• Platelets in atherothrombosis

  2002cited by this paper
• Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

  2002cited by this paper
• Genetic Evidence That Protease-activated Receptors Mediate Factor Xa Signaling in Endothelial Cells*

  2002cited by this paper
• Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation

  2002cited by this paper
• Binding of Thrombin to Glycoprotein Ib Accelerates the Hydrolysis of Par-1 on Intact Platelets*

  2001cited by this paper
• Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor

  2001cited by this paper
• Role of thrombin signalling in platelets in haemostasis and thrombosis

  2001cited by this paper
• Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.

  2001cited by this paper
• Protease-activated receptors in inflammation, neuronal signaling and pain.

  2001cited by this paper
• Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.

  2001cited by this paper
• Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins.

  2000cited by this paper
• Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors.

  2000cited by this paper
• PAR3 is a cofactor for PAR4 activation by thrombin

  2000cited by this paper
• Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.

  2000cited by this paper
• Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.

  2000cited by this paper
• Substrate-Assisted Catalysis of the PAR1 Thrombin Receptor

  2000cited by this paper
• Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.

  1999cited by this paper
• A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase.

  1999cited by this paper
• Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.

  1999cited by this paper
• Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.

  1999cited by this paper
• Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor.

  1999cited by this paper
• Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1.

  1999cited by this paper
• A dual thrombin receptor system for platelet activation

  1998cited by this paper
• Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo.

  1998cited by this paper
• Cloning and characterization of human protease-activated receptor 4.

  1998cited by this paper
• The Human Proteinase-activated Receptor-3 (PAR-3) Gene

  1998cited by this paper
• Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat.

  1998cited by this paper
• Defective platelet activation in G alpha(q)-deficient mice.

  1997cited by this paper
• Expression of thrombin receptors in human atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in vitro.

  1997cited by this paper
• Antithrombotic Strategies Targeting Thrombin Activities, Thrombin Receptors and Thrombin Generation

  1997cited by this paper
• Defective platelet activation in Gαq-deficient mice

  1997cited by this paper
• The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells.

  1996cited by this paper
• Biological Consequences of Thrombin Receptor Deficiency in Mice

  1996cited by this paper
• Development of potent thrombin receptor antagonist peptides.

  1996cited by this paper
• Regulation of endothelial cell gap formation and barrier dysfunction: Role of myosin light chain phosphorylation

  1995cited by this paper
• Determinants of Thrombin Receptor Cleavage. RECEPTOR DOMAINS INVOLVED, SPECIFICITY, AND ROLE OF THE P3 ASPARTATE (*)

  1995cited by this paper
• An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey.

  1995cited by this paper
• Mechanisms of Thrombin Receptor Agonist Specificity

  1995cited by this paper
• Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface

  1994cited by this paper
• Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.

  1994cited by this paper
• Identification of a novel thrombin receptor sequence required for activation-dependent responses.

  1994cited by this paper
• Receptor Mechanism of Thrombin‐Induced Endothelium‐Dependent and Endothelium‐Independent Coronary Vascular Effects in Dogs

  1993cited by this paper
• Thrombin receptor activating peptides induce Ca2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet‐derived growth factor mRNA expression in cultured endothelium

  1993cited by this paper
• Myocardial alpha-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression.

  1993cited by this paper
• Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor.

  1993cited by this paper
• Thrombin receptor expression in normal and atherosclerotic human arteries.

  1992cited by this paper
• Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.

  1991cited by this paper
• Domains specifying thrombin–receptor interaction

  1991cited by this paper
• The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity.

  1991cited by this paper
• Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140.

  1989cited by this paper

• Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study.

  2025cites this paper
• Linking thromboembolism to the pathogenesis of long COVID

  2025cites this paper
• Platelet Activation in Patients with Peripheral Artery Disease From 43 Sites: Assessment of Samples Transported by Overnight Mail

  2025cites this paper
• Gender-associated heterogeneity of F2RL3 methylation in peripheral blood highlights its associations with early-stage male lung cancer in the Chinese population.

  2025cites this paper
• Structural basis for the activation of proteinase-activated receptors PAR1 and PAR2

  2025cites this paper
• Dexmedetomidine Reduces Chronic Stress–Related Thrombosis in a Mouse FeCl3 Model

  2025cites this paper
• Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling

  2025cites this paper
• Structural basis of tethered agonism and G protein coupling of protease-activated receptors

  2024cites this paper
• Platelet Physiology

  2024cites this paper
• Mitigating Vascular Inflammation by Mimicking AIBP Mechanisms: A New Therapeutic End for Atherosclerotic Cardiovascular Disease

  2024cites this paper
• Protease-Activated Receptor 2 Controls Vascular Smooth Muscle Cell Proliferation in Cyclic AMP-Dependent Protein Kinase/Mitogen-Activated Protein Kinase Kinase 1/2-Dependent Manner

  2023cites this paper
• Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells

  2023cites this paper
• Suppression of Heart Failure With PAR1 Pepducin Technology in a Pressure Overload Model in Mice

  2023cites this paper
• Daboxin P, a phospholipase A2 of Indian Daboia russelii venom, modulates thrombin‐mediated platelet aggregation

  2023cites this paper
• Strong correlation between F2RL3 in the blood and osteoarthritis based on a retrospective cohort study

  2023cites this paper
• Integrated LC-MS/MS and network pharmacology approach for predictingactive ingredients and pharmacological mechanisms of Tribulus terrestris L. against cardiac diseases

  2023cites this paper
• Protease-Activated Receptor 1 in Human Carotid Atheroma Is Significantly Related to Iron Metabolism, Plaque Vulnerability, and the Patient’s Age

  2022cites this paper
• Pepducin-mediated GPCR signaling in the cardiovascular system.

  2022cites this paper
• The Role Of Clot Structure And Mechanics On Hemodynamics And Pharmacology

  2022cites this paper
• F2RL3 Methylation in the Peripheral Blood as a Potential Marker for the Detection of Coronary Heart Disease: A Case-Control Study

  2022cites this paper
• Emerging roles of Protease-Activated Receptors in Cardiometabolic Disorders.

  2022cites this paper
• Coagulation-independent effects of thrombin and factor Xa: role of protease-activated receptors in pulmonary hypertension.

  2022cites this paper
• No benefit of vorapaxar on walking performance in patients with intermittent claudication

  2021cites this paper
• Changes in Maternal Platelet Physiology during Gestation and Their Interaction with Trophoblasts

  2021cites this paper
• The Impact of Smoking on Clinical Outcomes after Percutaneous Coronary Intervention in Women Compared to Men

  2021cites this paper
• Gene expression analysis in NSAID-induced rat small intestinal disease model with the intervention of berberine by the liquid chip technology

  2021cites this paper
• A narrative review of low-dose rivaroxaban in patients with atherothrombotic cardiovascular disease: vascular protection beyond anticoagulation.

  2021cites this paper
• Endothelial cells and coagulation

  2021cites this paper
• Methylome Patterns of Cattle Adaptation to Heat Stress

  2021cites this paper
• Receptors | Proteinase-Activated Receptors

  2021cites this paper
• Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model

  2021cites this paper
• Astragalin Inhibits Cigarette Smoke-Induced Pulmonary Thrombosis and Alveolar Inflammation and Disrupts PAR Activation and Oxidative Stress-Responsive MAPK-Signaling

  2021cites this paper
• Genetic Diversity, Inbreeding Level, and Genetic Load in Endangered Snub-Nosed Monkeys (Rhinopithecus)

  2020cites this paper
• RECENT HIGHLIGHTS OF ATVB

  2020cites this paper
• Role of PAR1-Egr1 in the Initiation of Thoracic Aortic Aneurysm in Fbln4-Deficient Mice

  2020cites this paper
• Role of GPCRs in cancer

  2020cites this paper
• Blockade of PAR‐1 Signaling Attenuates Cardiac Hypertrophy and Fibrosis in Renin‐Overexpressing Hypertensive Mice

  2020cites this paper
• Lipid Receptor GPR31 (G-Protein–Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis

  2020cites this paper
• Targeting Platelet in Atherosclerosis Plaque Formation: Current Knowledge and Future Perspectives

  2020cites this paper
• Protease-activated receptor 1 (PAR1) inhibits synaptic NMDARs in mouse nigral dopaminergic neurons.

  2020cites this paper
• PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization

  2020cites this paper
• Mechanism of tanshinones and phenolic acids from Danshen in the treatment of coronary heart disease based on co-expression network

  2020cites this paper
• Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption

  2020cites this paper
• Coronary Artery Disease

  2020cites this paper
• Smoking-related changes in DNA methylation and gene expression are associated with cardio-metabolic traits

  2020cites this paper
• Protease-activated receptor signalling initiates α5β1-integrin-mediated adhesion in non-haematopoietic cells

  2020cites this paper
• Betanin-enriched red beet extract attenuated platelet activation and aggregation by suppressing Akt and P38 Mitogen-activated protein kinases phosphorylation

  2019cites this paper
• Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.

  2019cites this paper
• Laboratory Monitoring of Antiplatelet Therapy

  2019cites this paper
• Protease Activity in Vascular Disease.

  2019cites this paper
• Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice

  2019cites this paper
• Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease‐Activated Receptor Pathway

  2019cites this paper
• Welding Fume Exposure and Epigenetic Alterations: A Systematic Review

  2019cites this paper
• Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice

  2019cites this paper
• Characterization of the distinct mechanism of agonist-induced canine platelet activation

  2019cites this paper
• Applications of NMR in Cancer Research

  2019cites this paper
• Bioprofiles and mechanistic pathways associated with Cheyne-Stokes respiration: insights from the SERVE-HF trial

  2019cites this paper
• Conserved aging-related signatures of senescence and inflammation in different tissues and species

  2019cites this paper
• Coagulation Abnormalities in Sepsis

  2019cites this paper
• Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E–Deficient Mice

  2018cites this paper
• Protease-activated receptor 1 inhibits cholesterol efflux and promotes atherogenesis via cullin 3–mediated degradation of the ABCA1 transporter

  2018influential citation
• Noncanonical Matrix Metalloprotease 1–Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis

  2018cites this paper
• Phospholipase Cγ2 signalling contributes to the haemostatic effect of Notoginsenoside Ft1

  2018cites this paper
• Detection of Concordance between Transcriptional Levels of GPCRs and Receptor-Activity-Modifying Proteins

  2018cites this paper
• Cyclic Nucleotide-Directed Protein Kinases in Cardiovascular Inflammation and Growth

  2018influential citation
• Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?

  2018cites this paper
• University of Birmingham Atherothrombosis and Thromboembolism :

  2018cites this paper
• Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

  2018cites this paper
• Riluzole induces DNA double strand breaks in mGluR1 expressing human melanoma cells

  2018cites this paper
• Detection, assessment and modulation of myocardial inflammation

  2018cites this paper
• High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma

  2018cites this paper
• Phospholipase Cγ2 Signaling Cascade Contribute to the Antiplatelet Effect of Notoginsenoside Fc

  2018cites this paper
• Platelets in Acute Coronary Syndromes

  2017cites this paper
• Metalloproteinase-9 contributes to endothelial dysfunction in atherosclerosis via protease activated receptor-1

  2017cites this paper
• Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting

  2017cites this paper
• Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?

  2017cites this paper
• Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis

  2017cites this paper
• Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial

  2017cites this paper
• Ticagrelor: Effects Beyond the P2Y12 Receptor.

  2017cites this paper
• Functional Modulation of the Pattern Recognition Formyl Peptide Receptors in Neutrophils - Lipopeptides - allosteric modulators of G-protein coupled receptors

  2017cites this paper
• DIVERSE CLINICAL FUNCTIONS OF SERINE PROTEASE AND ITS INHIBITORS

  2017cites this paper
• Human neutrophil elastase induces endothelial cell apoptosis by activating the PERK‐CHOP branch of the unfolded protein response

  2017cites this paper
• Inhibition of plasmin generation in plasma by heparin, low molecular weight heparin, and a covalent antithrombin–heparin complex

  2017cites this paper
• Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process.

  2017cites this paper
• Transcriptome analysis of inflammation-related gene expression in endothelial cells activated by complement MASP-1

  2017cites this paper
• Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome

  2017cites this paper
• Blood-based omic profiling supports female susceptibility to tobacco smoke-induced cardiovascular diseases

  2017cites this paper
• Molecular and Experimental Basis for COX Inhibition in Cancer

  2016cites this paper
• Proteinase-activated receptors (PARs) as targets for antiplatelet therapy.

  2016cites this paper
• Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease

  2016cites this paper
• MicroRNA‐181b inhibits thrombin‐mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10

  2016cites this paper
• Evolution of the protease-activated receptor family in vertebrates

  2016cites this paper
• Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).

  2016cites this paper
• Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation

  2016cites this paper
• Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty

  2016cites this paper
• The Role of DNA Methylation in Cardiovascular Risk and Disease: Methodological Aspects, Study Design, and Data Analysis for Epidemiological Studies.

  2016cites this paper
• A Novel Approach To Antiplatelet Therapy: Targeting Protease Activated Receptor 4

  2016cites this paper
• Platelet Physiology

  2016cites this paper
• Protease receptor antagonism to target blood platelet therapies

  2016cites this paper
• Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2

  2016cites this paper